Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Summary

This is a Phase 2, multicenter study evaluating the efficacy and safety of mosunetuzumab + zanubrutinib (M+Z) used as salvage strategy in patients with R/R FL who have received at least one line of prior systemic therapy.

Timeline

Start

2024-10-23

Primary completion

2028-09-15

Completion

2033-09-15

Drugs

Indications